Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): review proposal 9 February 2015
Proposal to move the existing guidance to the static list
The planned date for review of TA242 is January 2015. TA240 was terminated because no submission was received, and the termination advice was issued in December 2011. Therefore there is no review date for TA240.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
No evidence related to these technologies for the second-line treatment of metastatic colorectal cancer has been identified that would lead to a change in the existing recommendations.
Consequently we propose that the recommendations for the second-line use of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) from TA242 should move to the ‘static list’.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
It is also proposed that the termination advice in TA240 should remain in place.
Alongside this, the landing pages for TA240 and TA242 will be updated to reflect the change to the marketing authorisations for panitumumab and cetuximab.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 06 February 2015